Synthesis, characterization and biological evaluation of ureidofibrate-like derivatives endowed with peroxisome proliferator-activated receptor activity

Journal of Medicinal Chemistry

Volumn 55, Issue 1, 2012, Pages 37-54

  Porcelli, L ^a   Gilardi, F ^b,g   Laghezza, A ^c   Piemontese, L ^c   Mitro, N ^b   Azzariti, A ^a   Altieri, F ^d   Cervoni, L ^d   Fracchiolla, G ^c   Giudici, M ^b   Guerrini, U ^b   Lavecchia, A ^e   Montanari, R ^f   Di Giovanni, C ^e   Paradiso, A ^a   Pochetti, G ^f   Simone, G M ^a   Tortorella, P ^c   Crestani, M ^b   Loiodice, F ^c  

^a NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF BARI   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^f CNR   (Italy)

^g UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRIC ACID DERIVATIVE; INSULIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ADIPOCYTE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; COLON CANCER; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG SCREENING; DRUG SYNTHESIS; FIBROBLAST; GENE EXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; INSULIN RESISTANCE; INTRAABDOMINAL FAT; LIPID DIET; MALE; MOUSE; NONHUMAN;

ADIPOCYTES; ANIMALS; ANTINEOPLASTIC AGENTS; BENZOXAZOLES; BODY WEIGHT; CALORIMETRY; CELL DIFFERENTIATION; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; CRYSTALLOGRAPHY, X-RAY; DRUG PARTIAL AGONISM; DRUG SCREENING ASSAYS, ANTITUMOR; FIBRIC ACIDS; FIBROBLASTS; GENE EXPRESSION PROFILING; HUMANS; INSULIN RESISTANCE; INTRA-ABDOMINAL FAT; LIVER; MICE; MICE, INBRED C57BL; MODELS, MOLECULAR; PPAR ALPHA; PPAR GAMMA; PROPIONIC ACIDS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; UREA;

EID: 84855839232     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm201306q     Document Type: Article

References (65)

1. Berger, J. P.; Akiyama, T. E.; Meinke, P. T. PPARs: therapeutic targets for metabolic disease Trends Pharmacol. Sci. 2005, 26, 244-251
2. Berger, J.; Moller, D. E. The mechanisms of action of PPARs Annu. Rev. Med. 2002, 53, 409-435
3. Kliewer, S. A.; Sundseth, S. S.; Jones, S. A.; Brown, P. J.; Wisely, G. B.; Koble, C. S.; Devchand, P.; Wahli, W.; Willson, T. M.; Lenhard, J. M.; Lehmann, J. M. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 4318-4323
4. Nolte, R. T.; Wisely, G. B.; Westin, S.; Cobb, J. E.; Lambert, M. H.; Kurokawa, R.; Rosenfeld, M. G.; Willson, T. M.; Glass, C. K.; Milburn, M. V. Ligand binding and co-activator assembly of the peroxisome proliferatoractivated receptor-gamma Nature 1998, 395, 137-143
5. Gampe, R. T., Jr.; Montana, V. G.; Lambert, M. H.; Miller, A. B.; Bledsoe, R. K.; Milburn, M. V.; Kliewer, S. A.; Willson, T. M.; Xu, H. E. Asymmetry in the PPAR[gamma]/RXR[alpha] crystal structure reveals the molecular basis of heterodimerization among nuclear receptors Mol. Cell 2000, 5, 545-555
6. Willson, T. M.; Brown, P. J.; Sternbach, D. D.; Henke, B. R. The PPARs: from orphan receptors to drug discovery J. Med. Chem. 2000, 43, 527-550
7. Evans, R. M.; Barish, G. D.; Wang, Y. X. PPARs and the complex journey to obesity Nat. Med. 2004, 10, 355-361
8. Semple, R. K.; Chatterjee, V. K.; ORahilly, S. PPAR gamma and human metabolic disease J. Clin. Invest. 2006, 116, 581-589
9. Schoonjans, K.; Auwerx, J. Thiazolidinediones: an update Lancet 2000, 355, 1008-1010
10. Nesto, R. W.; Bell, D.; Bonow, R. O.; Fonseca, V.; Grundy, S. M.; Horton, E. S.; Le Winter, M.; Porte, D.; Semenkovich, C. F.; Smith, S.; Young, L. H.; Kahn, R. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association Diabetes Care 2004, 27, 256-263
11. Bodmer, M.; Meier, C.; Kraenzlin, M. E.; Meier, C. R. Risk of fractures with glitazones: a critical review of the evidence to date Drug. Saf. 2009, 32, 539-547
12. Rocchi, S.; Picard, F.; Vamecq, J.; Gelman, L.; Potier, N.; Zeyer, D.; Dubuquoy, L.; Bac, P.; Champy, M. F.; Plunket, K. D.; Leesnitzer, L. M.; Blanchard, S. G.; Desreumaux, P.; Moras, D.; Renaud, J. P.; Auwerx, J. A unique PPARgamma ligand with potent insulin-sensitizing yet weak adipogenic activity Mol. Cell 2001, 8, 737-747
13. Berger, J. P.; Petro, A. E.; Macnaul, K. L.; Kelly, L. J.; Zhang, B. B.; Richards, K.; Elbrecht, A.; Johnson, B. A.; Zhou, G.; Doebber, T. W.; Biswas, C.; Parikh, M.; Sharma, N.; Tanen, M. R.; Thompson, G. M.; Ventre, J.; Adams, A. D.; Mosley, R.; Surwit, R. S.; Moller, D. E. Distinct properties and advantages of a novel peroxisome proliferator-activated protein [gamma] selective modulator Mol. Endocrinol. 2003, 17, 662-676
14. Misra, P.; Chakrabarti, R.; Vikramadithyan, R. K.; Bolusu, G.; Juluri, S.; Hiriyan, J.; Gershome, C.; Rajjak, A.; Kashireddy, P.; Yu, S.; Surapureddi, S.; Qi, C.; Zhu, Y. J.; Rao, M. S.; Reddy, J. K.; Ramanujam, R. PAT5A: a partial agonist of peroxisome proliferator-activated receptor gamma is a potent antidiabetic thiazolidinedione yet weakly adipogenic J. Pharmacol. Exp. Ther. 2003, 306, 763-771
15. Minoura, H.; Takeshita, S.; Ita, M.; Hirosumi, J.; Mabuchi, M.; Kawamura, I.; Nakajima, S.; Nakayama, O.; Kayakiri, H.; Oku, T.; Ohkubo-Suzuki, A.; Fukagawa, M.; Kojo, H.; Hanioka, K.; Yamasaki, N.; Imoto, T.; Kobayashi, Y.; Mutoh, S. Pharmacological characteristics of a novel nonthiazolidinedione insulin sensitizer, FK614 Eur. J. Pharmacol. 2004, 494, 273-281
16. Acton, J. J., III; Black, R. M.; Jones, A. B.; Moller, D. E.; Colwell, L.; Doebber, T. W.; Macnaul, K. L.; Berger, J.; Wood, H. B. Benzoyl 2-methyl indoles as selective PPARgamma modulators Bioorg. Med. Chem. Lett. 2005, 15, 357-362
17. Dropinski, J. F.; Akiyama, T.; Einstein, M.; Habulihaz, B.; Doebber, T.; Berger, J. P.; Meinke, P. T.; Shi, G. Q. Synthesis and biological activities of novel aryl indole-2-carboxylic acid analogs as PPARgamma partial agonists Bioorg. Med. Chem. Lett. 2005, 15, 5035-5038
18. Reifel-Miller, A.; Otto, K.; Hawkins, E.; Barr, R.; Bensch, W. R.; Bull, C.; Dana, S.; Klausing, K.; Martin, J. A.; Rafaeloff-Phail, R.; Rafizadeh-Montrose, C.; Rhodes, G.; Robey, R.; Rojo, I.; Rungta, D.; Snyder, D.; Wilbur, K.; Zhang, T.; Zink, R.; Warshawsky, A.; Brozinick, J. T. A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia Mol. Endocrinol. 2005, 19, 1593-1605
19. Martín, J. A.; Brooks, D. A.; Prieto, L.; González, R.; Torrado, A.; Rojo, I.; López de Uralde, B.; Lamas, C.; Ferreto, R.; Dolores Martín-Ortega, M.; Agejas, J.; Parra, F.; Rizzo, J. R.; Rhodes, G. A.; Robey, R. L.; Alt, C. A.; Wendel, S. R.; Zhang, T. Y.; Reifel-Miller, A.; Montrose-Rafizadeh, C.; Brozinick, J. T.; Hawkins, E.; Misener, E. A.; Briere, D. A.; Ardecky, R.; Fraser, J. D.; Warshawsky, A. M. 2-Alkoxydihydrocinnamates as PPAR agonists. Activity modulation by the incorporation of phenoxy substituents Bioorg. Med. Chem. Lett. 2005, 15, 51-55
20. Burgermeister, E.; Schnoebelen, A.; Flament, A.; Benz, J.; Stihle, M.; Gsell, B.; Rufer, A.; Ruf, A.; Kuhn, B.; Märki, H. P.; Mizrahi, J.; Sebokova, E.; Niesor, E.; Meyer, M. A novel partial agonist of peroxisome proliferator-activated receptor-gamma (PPARgamma) recruits PPARgamma- coactivator-1alpha, prevents triglyceride accumulation, and potentiates insulin signaling in vitro Mol. Endocrinol. 2006, 20, 809-830
21. Allen, T.; Zhang, F.; Moodie, S. A.; Clemens, L. E.; Smith, A.; Gregoire, F.; Bell, A.; Muscat, G. E.; Gustafson, T. A. Halofenate is a selective peroxisome proliferator-activated receptor gamma modulator with antidiabetic activity Diabetes 2006, 55, 2523-2533
22. Carmona, M. C.; Louche, K.; Lefebvre, B.; Pilon, A.; Hennuyer, N.; Audinot-Bouchez, V.; Fievet, C.; Torpier, G.; Formstecher, P.; Renard, P.; Lefebvre, P.; Dacquet, C.; Staels, B.; Casteilla, L.; Pénicaud, L. S 26948: a new specific peroxisome proliferator activated receptor gamma modulator with potent antidiabetes and antiatherogenic effects Diabetes 2007, 56, 2797-2808
23. Kim, M. K.; Chae, Y. N.; Kim, H. S.; Choi, S. H.; Son, M. H.; Kim, S. H.; Kim, J. K.; Moon, H. S.; Park, S. K.; Shin, Y. A.; Kim, J. G.; Lee, C. H.; Lim, J. I.; Shin, C. Y. PAR-1622 is a selective peroxisome proliferator-activated receptor gamma partial activator with preserved antidiabetic efficacy and broader safety profile for fluid retention Arch. Pharm. Res. 2009, 32, 721-727
24. Motani, A.; Wang, Z.; Weiszmann, J.; McGee, L. R.; Lee, G.; Liu, Q.; Staunton, J.; Fang, Z.; Fuentes, H.; Lindstrom, M.; Liu, J.; Biermann, D. H.; Jaen, J.; Walker, N. P.; Learned, R. M.; Chen, J. L.; Li, Y. INT131: a selective modulator of PPAR gamma J. Mol. Biol. 2009, 386, 1301-1311
25. Pochetti, G.; Godio, C.; Mitro, N.; Caruso, D.; Galmozzi, A.; Scurati, S.; Loiodice, F.; Fracchiolla, G.; Tortorella, P.; Laghezza, A.; Lavecchia, A.; Novellino, E.; Mazza, F.; Crestani, M. Insights into the mechanism of partial agonism: crystal structures of the peroxisome proliferator-activated receptor gamma ligand-binding domain in the complex with two enantiomeric ligands J. Biol. Chem. 2007, 282, 17314-17324
26. Pochetti, G.; Mitro, N.; Lavecchia, A.; Gilardi, F.; Besker, N.; Scotti, E.; Aschi, M.; Re, N.; Fracchiolla, G.; Laghezza, A.; Tortorella, P.; Montanari, R.; Novellino, E.; Mazza, F.; Crestani, M.; Loiodice, F. Structural insight into peroxisome proliferator-activated receptor γ binding of two ureidofibrate-like enantiomers by molecular dynamics, cofactor interaction analysis, and site-directed mutagenesis J. Med. Chem. 2010, 53, 4354-4366
27. Sarraf, P.; Muller, E.; Jones, D.; Holden, S.; Tomoyasu, S.; Koeffler, H. P. Differentiation and reversal of malignant changes in colon cancer through PPARγ differentiation Nat. Med. 1998, 4, 1046-1052
28. Hisatake, J. I.; Ikezoe, T.; Carey, M.; Holden, S.; Tomoyasu, S.; Koeffler, H. P. Downregulation of prostate-specific antigen expression by ligands for peroxisome proliferator-activated receptor γ in human prostate cancer Cancer Res. 2000, 60, 5494-5498
29. Liu, H.; Zang, C.; Fenner, M. H.; Possinger, K.; Elstner, E. PPAR gamma ligands and ATRA inhibit the invasion of human breast cancer cells in vitro Breast Cancer Res. Treat. 2003, 79, 63-74
30. Grommes, C.; Landreth, G. E.; Heneka, M. T. Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists Lancet Oncol. 2004, 5, 419-429
31. Theocharis, S.; Margeli, A.; Vielh, P.; Kouraklis, G. Peroxisome proliferator-activated receptor-gamma ligands as cell-cycle modulators Cancer Treat. Rev. 2004, 30, 545-554
32. Pinelli, A.; Godio, C.; Laghezza, A.; Mitro, N.; Fracchiolla, G.; Tortorella, V.; Lavecchia, A.; Novellino, E.; Fruchart, J. C.; Staels, B.; Crestani, M.; Loiodice, F. Synthesis, biological evaluation, and molecular modeling investigation of new chiral fibrates with PPARalpha and PPARgamma agonist activity J. Med. Chem. 2005, 48, 5509-5519
33. Fracchiolla, G.; Laghezza, A.; Piemontese, L.; Carbonara, G.; Lavecchia, A.; Tortorella, P.; Crestani, M.; Novellino, E.; Loiodice, F. Synthesis, biological evaluation, and molecular modeling investigation of chiral phenoxyacetic acid analogues with PPARalpha and PPARgamma agonist activity ChemMedChem 2007, 2, 641-654
34. Fracchiolla, G.; Lavecchia, A.; Laghezza, A.; Piemontese, L.; Trisolini, R.; Carbonara, G.; Tortorella, P.; Novellino, E.; Loiodice, F. Synthesis, biological evaluation, and molecular modeling investigation of chiral 2-(4-chloro-phenoxy)-3-phenyl-propanoic acid derivatives with PPARalpha and PPARgamma agonist activity Bioorg. Med. Chem. 2008, 16, 9498-9510
35. Fracchiolla, G.; Laghezza, A.; Piemontese, L.; Tortorella, P.; Mazza, F.; Montanari, R.; Pochetti, G.; Lavecchia, A.; Novellino, E.; Pierno, S.; Conte Camerino, D.; Loiodice, F. New 2-aryloxy-3-phenyl-propanoic acids as peroxisome proliferator-activated receptors alpha/gamma dual agonists with improved potency and reduced adverse effects on skeletal muscle function J. Med. Chem. 2009, 52, 6382-6393
36. GOLD, version 5.0.1; CCDC Software Limited: Cambridge, U.K., 2008.
37. Jones, G.; Willett, P.; Glen, R. C.; Leach, A. R.; Taylor, R. Development and validation of a genetic algorithm for flexible docking J. Mol. Biol. 1997, 267, 727-748
38. Schulz-Gasch, T.; Stahl, M. Binding site characteristics in structure-based virtual screening: evaluation of current docking tools J. Mol. Model 2003, 9, 47-57
39. Wang, R.; Lu, Y.; Wang, S. Comparative evaluation of 11 scoring functions for molecular docking J. Med. Chem. 2003, 46, 2287-2303
40. Kellenberger, E.; Rodrigo, J.; Muller, P.; Rognan, D. Comparative evaluation of eight docking tools for docking and virtual screening accuracy Proteins: Struct., Funct., Bioinf. 2004, 57, 225-242
41. Warre, G. L.; Andrews, C. W.; Capelli, A. M.; Clarke, B.; LaLonde, J.; Lambert, M. H.; Lindvall, M.; Nevins, N.; Semus, S. F.; Senger, S.; Tedesco, G.; Wall, I. D.; Woolven, J. M.; Peishoff, C. E.; Head, M. S. A critical assessment of docking programs and scoring functions J. Med. Chem. 2006, 49, 5912-5931
42. Verdonk, M. L.; Cole, J. C.; Hartshorn, M. J.; Murray, C. W.; Taylor, R. D. Improved protein-ligand docking using GOLD Proteins: Struct., Funct., Genet. 2003, 52, 609-623
43. Eldridge, M. D.; Murray, C. W.; Auton, T. R.; Paolini, G. V.; Mee, R. P. Empirical scoring functions: I. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes J. Comput.-Aided Mol. Des. 1997, 11, 425-445
44. Rubenstrunk, A.; Hanf, R.; Hum, D. W.; Fruchart, J.-C.; Staels, B. Safety issues and prospects for future generations of PPAR modulators Biochim. Biophys. Acta 2007, 1771, 1065-1081
45. Peraza, M. A.; Burdick, A. D.; Marin, H. E.; Gonzalez, F. J.; Peters, J. M. The toxicology of ligands for peroxisome proliferator-activated receptors (PPAR) Toxicol. Sci. 2006, 90, 269-295
46. Cheung, C.; Akiyama, T. E.; Ward, J. M.; Nicol, C. J.; Feigenbaum, L.; Vinson, C.; Gonzalez, F. J. Diminished hepatocellular proliferation in mice humanized for the nuclear receptor peroxisome proliferator-activated receptor α Cancer Res. 2004, 64, 3849-3854
47. Després, J.-P.; Lemieux, I. Abdominal obesity and metabolic syndrome Nature 2006, 444, 881-887
48. Kahn, S. E.; Hull, R. L.; Utzschneider, K. M. Mechanisms linking obesity to insulin resistance and type 2 diabetes Nature 2006, 444, 840-846
49. Heikkinen, S.; Argmann, C. A.; Champy, M.-F.; Auwerx, J. Evaluation of glucose homeostasis Curr. Protoc. Mol. Biol. 2007, 29B.3.1-29B.3.22
50. Shearer, B. G.; Billin, A. N. The next generation of PPAR drugs: Do we have the tools to find them? Biochim. Biophys. Acta 2007, 1771, 1082-1093
51. Nissen, S. E.; K. Wolski, K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes N. Engl. J. Med. 2007, 356, 2457-2471
52. Mattison, Y. B.; Putten, V. V.; Chan, D.; Winn, R.; Geraci, M. W.; Nemenoff, R. A. Peroxisome proliferator-activated receptor-γ (PPARγ) inhibits tumorigenesis by reversing the undifferentiated phenotype of metastatic non-small-cell lung cancer cells (NSCLC) Oncogene 2005, 24, 1412-1422
53. Leesnitzer, L. M.; Parks, D. J.; Bledsoe, R. K.; Cobb, J. E.; Collins, J. L.; Consler, T. G.; Davis, R. G.; Hull-Ryde, E. A.; Lenhard, J. M.; Patel, L.; Plunket, K. D.; Shenk, J. L.; Stimmel, J. B.; Therapontos, C.; Willson, T. M.; Blanchard, S. G. Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator-activated receptors by GW9662 Biochemistry 2002, 41, 6640-6650
54. Seargent, J. M.; Yates, E. A.; Gill, J. H. GW9662, a potent antagonist of PPARγ, inhibits growth of breast tumour cells and promotes the anticancer effects of the PPARγ agonist rosiglitazone, independently of PPARγ activation Br. J. Pharmacol. 2004, 143, 933-937
55. Raspe, E.; Madsen, L.; Lefebvre, A. M.; Leitersdorf, I.; Gelman, L.; Peinado-Onsurbe, J.; Dallongeville, J.; Fruchart, J.-C.; Berge, R.; Staels, B. Modulation of rat liver apolipoprotein gene expression and serum lipid levels by tetradecylthioacetic acid (TTA) via PPARalpha activation J. Lipid Res. 1999, 40, 2099-2110
56. Hollon, T.; Yoshimura, F. K. Variation in enzymatic transient gene expression assays Anal. Biochem. 1989, 182, 411-418
57. Sturtevant, J. M. Biochemical Applications of Differential Scanning Calorimetry Annu. Rev. Phys. Chem. 1987, 38, 463-488
58. Fukada, H.; Takahashi, K. Enthalpy and heat capacity changes for the proton dissociation of various buffer components in 0.1 M potassium chloride Proteins 1998, 33, 159-166
59. Molecular Operating Environment (MOE), version 2005.06; Chemical Computing Group, Inc.: Montreal, Canada, 2005.
60. Huang, C. C.; Couch, G. S.; Pettersen, E. F.; Ferrin, T. E. Chimera: an extensible molecular modelling application constructed using standard components Pac. Symp. Biocomput. 1996, 1, 724 http://www.cgl.ucsf.edu/chimera
61. Leslie, A. G. W. Recent changes to the MOSFLM package for processing film and image plate data. Jt. CCP4 ESF-EACMB Newslett. Protein Crystallogr. 1992, 26, 27-33
62. Navaza, J. AMoRe: an automated package for molecular replacement Acta Crystallogr., Sect. A 1994, 50, 157-163
63. Brunger, A. T.; Adams, P. D.; Clore, G. M.; DeLano, W. L.; Gros, P.; Grosse-Kunstleve, R. W.; Jiang, J. S.; Kuszewski, J.; Nilges, M.; Pannu, N. S.; Read, R. J.; Rice, L. M.; Simonson, T.; Warren, G. L. Crystallography NMR system: a new software suite for macromolecular structure determination Acta Crystallogr., Sect. D 1998, 54, 905-921
64. Rieusset, J.; Touri, F.; Michalik, L.; Escher, P.; Desvergne, B.; Niesor, E.; Wahli, W. A new selective peroxisome proliferator-activated receptor gamma antagonist with antiobesity and antidiabetic activity Mol. Endocrinol. 2002, 16, 2628-2644
65. Van Engeland, M.; Nieland, L. J. W.; Ramaekers, F. C. S.; Schutte, B.; Reutelingsperger, C. P. M. Annexin V-affinity assay: a review on an apoptosis detection system based on phosphatidylserine exposure Cytometry 1998, 31, 1-9